Navitoclax

Navitoclax has been studied in 292 papers since 2010: 2 trials and 16 observational studies in people, 185 in animals, 56 in cells, 31 reviews; 67 in the past year. Its furthest trials in people are at phase 3. The newest story, Nov 16, 2026: “Protein levels alter drug sensitivity in lab-grown human cells”.

InterventionSenolyticsPhase 3

292 papers study it7 more mention it281 findingsUpdated

PubChemMeSH

Research on it is growing about as fast as aging research as a whole: 47 papers in the latest year counted

6 new papers in 30 daysSee all 299 papers on navitoclax

At a glance

Navitoclax reduces cellular senescence in mice across independent labs, although a finding shows no clear effect and inflammation changes in both directions. It increases mortality in mice with advanced atherosclerosis and causes thrombocytopenia in human trials, also reproduced by independent labs. Its registered trials are not classified as aging trials; most are developer-sponsored.

281 findings in 123 papers from 2010 to 2026, 13 of them since April 2026

Independent labs found the same change in cells, mice and people. 82 independent labs in 20 countries; 28 trials, none about aging, 10 with no results posted.

“Thrombocytopenia and neutropenia were the serious common toxicities with grade 3 or 4 thrombocytopenia or neutropenia observed in 29 and 17 patients, respectively.”
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityThe Lancet. Oncology2010doi:10.1016/s1470-2045(10)70261-8

4 of its findings point the other way.

Cells, mice and humans: replicated by independent labs. Worms or flies: nothing yet.
  • 82 independent labs in 20 countries
  • 4 findings against
  • 28 trials, none about aging, 10 with no results posted
  • Funders: National Institutes of Health and others
  • 41 of 275 findings with company ties
  • 17 of 28 trials sponsored by its developers
  • Human trial2
  • Humans16
  • Animals184
  • Model organisms1
  • Cells56
  • In silico1

Studies in people

1 study gave navitoclax to people and measured what changed.

What changedDesignPeopleSource

up: Induces partial response

up: Raises the risk of thrombocytopenia29 patients

down: Decreases platelet count

Trial21-day cycles, given for 14 or 21 days per cycle55 peoplemedian age of 59 yearsSubjects with a histologically confirmed lymphoid malignancyThe Lancet. Oncology, Nov 18, 2010

What did studies of navitoclax find?

198

Studies of navitoclax measured 198 outcomes; the most studied are cellular senescence (20 studies), inflammation (9) and senescence-associated secretory phenotype (SASP) (7).

Cellular senescence

downin mice13downin human cells2downin mouse cells2downin rats2+1−80%

20 studies
  1. Navitoclax decreases cellular senescence in human cells.

    “Pharmacologic reduction of senescent cells with Navitoclax shifts aged RPE toward a younger transcriptional profile”

    Cellsretinal pigment epithelium

    Senescence targeting re-enables injury-responsive repair in a human RPE aging model

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

  2. Navitoclax inhibits cellular senescence in HSD-fed mice.

    “Navitoclax treatment reduced senescence markers, restored vasodilation of mesenteric arteries, and improved vascular contractility.”

    Animalsin HSD-fed mice

    High-Salt Diet-Induced Endothelial Dysfunction Is Mediated by Cellular Senescence

    Journal of the American Heart Association

  3. Navitoclax decreases cellular senescence in mice with Tsc1 deletion in fibroblasts, endothelial cells or alveolar epithelial cells.

    “which were all abrogated by treatment with the senolytic agent ABT-263”

    Animalsin mice with Tsc1 deletion in fibroblasts, endothelial cells or alveolar epithelial cellslung

    Lung mTOR activation leads to lung fibrosis or emphysema via senescence of specific lung cells

    Scientific reports

  4. Navitoclax decreases cellular senescence in rats after experimental ischemic stroke (tMCAO) (-80%).

    “navitoclax significantly reduced levels of SA-β-gal (by 80%), lipofuscin (by 91%), and Checkpoint kinase 2 (Chk2; by 69%) in the ischemic hemisphere”

    Animalsafter experimental ischemic stroke (tMCAO)i.p.brain (ischemic hemisphere)6 x 10 mg/kgbetween days 3 and 13males

    The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke

    Pharmaceuticals (Basel, Switzerland)

  5. Navitoclax decreases cellular senescence in APP/PS1 mice.

    “ABT263 protected neurons against Aβ pathology, reduced the accumulation of senescent cells, and improved cognitive decline by enhancing PI3K/AKT/GSK-3 activity.”

    Animalsin APP/PS1 micehippocampustwo cycles of five days eachn = 16

    ABT263 Ameliorates Cellular Senescence, Aβ-Dependent Pathology and Cognitive Decline in Aged APP/PS1 Mice via Regulating PI3K/AKT/GSK-3β Pathways

    Cell biochemistry and biophysics

  6. Navitoclax decreases cellular senescence in mice (compared with DMSO vehicle controls).

    “topical ABT-263 effectively reduced several senescence markers in aged skin”

    Animalscompared with DMSO vehicle controlstopicalskin5-day period

    Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing

    Aging

  7. Navitoclax decreases cellular senescence in 1,25(OH)2D-insufficient mice.

    “ABT263 corrected bone cell senescence and SASP caused by 1,25(OH)2D insufficiency by reducing the expression of senescence and SASP-related genes and proteins.”

    Animalsin 1,25(OH)2D-insufficient micebone

    The senolytic agent ABT263 ameliorates osteoporosis caused by active vitamin D insufficiency through selective clearance of senescent skeletal cells

    Journal of orthopaedic translation

  8. Navitoclax decreases cellular senescence in spontaneously and TNF-induced senescent CAFs.

    “senolytic drugs, navitoclax and the combination of dasatinib/quercetin, reduced the number of spontaneously senescent and TNF-induced senescent CAFs.”

    Cellsin spontaneously and TNF-induced senescent CAFs

    The Differential Effect of Senolytics on SASP Cytokine Secretion and Regulation of EMT by CAFs

    International journal of molecular sciences

  9. Navitoclax inhibits cellular senescence in chronic graft-versus-host disease mice.

    “The expression of these cellular senescence-associated molecules was considerably suppressed in ABT-263-treated eyelids compared to that in vehicle-treated ones.”

    Animalsin chronic graft-versus-host disease miceeyelid

    Cellular senescence promotes meibomian gland dysfunction in a chronic graft-versus-host disease mouse model

    The ocular surface

  10. Navitoclax decreases cellular senescence in SOX6-induced senescent cervical cancer cells.

    “ABT-263 (navitoclax) and ABT-199 (venetoclax), two classic senolytics, can specifically eliminate the SOX6-induced senescent cervical cancer cells”

    Cellsin SOX6-induced senescent cervical cancer cells

    MAP4K4 and WT1 mediate SOX6-induced cellular senescence by synergistically activating the ATF2-TGFβ2-Smad2/3 signaling pathway in cervical cancer

    Molecular oncology

All 20

More on Cellular senescence

Inflammation

downin mice4downin rats2upin mice1downin mouse cells1+1

9 studies
  1. Navitoclax decreases inflammation in mouse cells.

    “Navitoclax-loaded nCVTs retained senolytic activity and reduced inflammatory signaling and fibrotic activation in vitro.”

    CellsnCVT-loaded

    Drug-filled particles reduced liver fat buildup in mice

    Journal of controlled release : official journal of the Controlled Release Society

  2. Navitoclax decreases inflammation in mice (aged mice infected with influenza).

    “ABT-263 treatment significantly reduced lung inflammation in aged mice”

    Animalsaged mice infected with influenzalung

    Senolytic Treatment Reduces Acute and Chronic Lung Inflammation in an Aged Mouse Model of Influenza

    Aging cell

  3. Navitoclax decreases inflammation in ZSF1-Obese rats.

    “Senescent cell clearance decreased circulating B-type natriuretic peptide levels and attenuated inflammation, vascular remodelling, and cardiac fibrosis.”

    Animalsin ZSF1-Obese rats

    Pharmacological clearance of senescent cells reduces inflammation, endothelial damage and cardiac fibrosis in HFpEF

    Cardiovascular research

  4. Navitoclax decreases inflammation in mice (periodontitis).

    “Senolytics via Navitoclax successfully alleviated inflammation and bone loss in periodontitis”

    Animalsperiodontitis

    CD81⁺ senescent-like fibroblasts exaggerate inflammation and activate neutrophils via C3/C3aR1 axis in periodontitis

    eLife

  5. Navitoclax induces inflammation in mice (temporary response).

    “ABT-263 also triggered a temporary inflammatory response and macrophage infiltration in the skin.”

    Animalstemporary responsetopicalskin

    Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing

    Aging

  6. Navitoclax decreases inflammation in chronic graft-versus-host disease mice.

    “Pathological and immunohistochemical examinations revealed significant reductions in eyelid tissue inflammation and pathological fibrosis in the ABT-263 group compared to that in the vehicle-treated group.”

    Animalsin chronic graft-versus-host disease miceeyelid

    Cellular senescence promotes meibomian gland dysfunction in a chronic graft-versus-host disease mouse model

    The ocular surface

  7. Navitoclax decreases inflammation in zebrafish.

    “the senolytic drugs dasatinib, navitoclax, and venetoclax have an anti-inflammatory effect that results in the amelioration of chronic inflammation.”

    Animalsin zebrafish models of chronic inflammation (spint1a mutant and high-fat diet-induced NAFLD/NASH)

    Senescence-Independent Anti-Inflammatory Activity of the Senolytic Drugs Dasatinib, Navitoclax, and Venetoclax in Zebrafish Models of Chronic Inflammation

    International journal of molecular sciences

  8. Navitoclax decreases inflammation in rats (myocardial ischemia-reperfusion injury).

    “ameliorated inflammatory responses and attenuated adverse remodeling”

    Animalsmyocardial ischemia-reperfusion injurynanoparticleheart

    Local delivery of a senolytic drug in ischemia and reperfusion-injured heart attenuates cardiac remodeling and restores impaired cardiac function

    Acta biomaterialia

  9. Navitoclax decreases inflammation in mice (angiotensin II-induced heart failure).

    “navitoclax ameliorated Ang II-induced cardiac fibrosis, hypertrophy, and the inflammatory response”

    Animalsangiotensin II-induced heart failuremyocardial tissue

    Senolytic Agent Navitoclax Inhibits Angiotensin II-Induced Heart Failure in Mice

    Journal of cardiovascular pharmacology

More on Inflammation

Senescence-associated secretory phenotype (SASP)

downin mice5downin cells1downin humans1

7 studies
  1. Navitoclax decreases senescence-associated secretory phenotype (SASP) in APP/PS1 mice.

    “ABT263 treatment led to a decline in senescence-associated β-galactosidase activity, p16 senescence-related gene expression, and the expression of SASP-associated proteins, including IL-6, IL-8, and MMP-1.”

    Animalsin APP/PS1 micehippocampustwo cycles of five days eachn = 16

    ABT263 Ameliorates Cellular Senescence, Aβ-Dependent Pathology and Cognitive Decline in Aged APP/PS1 Mice via Regulating PI3K/AKT/GSK-3β Pathways

    Cell biochemistry and biophysics

  2. Navitoclax decreases senescence-associated secretory phenotype (SASP) in 1,25(OH)2D-insufficient mice.

    “ABT263 corrected bone cell senescence and SASP caused by 1,25(OH)2D insufficiency by reducing the expression of senescence and SASP-related genes and proteins.”

    Animalsin 1,25(OH)2D-insufficient micebone

    The senolytic agent ABT263 ameliorates osteoporosis caused by active vitamin D insufficiency through selective clearance of senescent skeletal cells

    Journal of orthopaedic translation

  3. Navitoclax decreases senescence-associated secretory phenotype (SASP) in humans (human skin graft mouse model).

    “Senescent human skin treated with ABT-263 exhibited a decrease in the number of senescent cells and in the expression of aging-related secretory phenotype molecules”

    Animalshuman skin graft mouse modelskin

    Navitoclax (ABT-263) Rejuvenates Human Skin by Eliminating Senescent Dermal Fibroblasts in a Mouse/Human Chimeric Model

    Rejuvenation research

  4. Navitoclax decreases senescence-associated secretory phenotype (SASP) in LPS- and CCl4-induced ACLF mice.

    “downregulation of mRNA expression of senescence-associated secretory phenotype factors”

    Animalsin LPS- and CCl4-induced ACLF miceliver

    Navitoclax improves acute-on-chronic liver failure by eliminating senescent cells in mice

    Hepatology research : the official journal of the Japan Society of Hepatology

  5. Navitoclax inhibits senescence-associated secretory phenotype (SASP) in mice (UHMWPE particle-induced osteolysis).

    “inhibit the secretion and inflammatory state of the senescence-associated secretory phenotype (SASP).”

    AnimalsUHMWPE particle-induced osteolysis

    Clearance of senescent cells by navitoclax (ABT263) rejuvenates UHMWPE-induced osteolysis

    International immunopharmacology

  6. Navitoclax decreases senescence-associated secretory phenotype (SASP) in mice (hairless mice treated with ABT-263).

    “as well as decreased senescence-associated secretory phenotypes, such as MMP-1 and IL-6.”

    Animalshairless mice treated with ABT-263dorsal skin10 days

    Attenuation of intrinsic ageing of the skin via elimination of senescent dermal fibroblasts with senolytic drugs

    Journal of the European Academy of Dermatology and Venereology : JEADV

  7. Navitoclax decreases senescence-associated secretory phenotype (SASP) in cells (through elimination of senescent cells).

    “selective elimination of senescent cells alleviates SASP and micronuclei-mediated the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) activation”

    Cellsthrough elimination of senescent cells

    Characterization of radiation-induced micronuclei associated with premature senescence, and their selective removal by senolytic drug, ABT-263

    Mutation research. Genetic toxicology and environmental mutagenesis

More on Senescence-associated secretory phenotype (SASP)

Apoptosis

upin human cells3upin cells2upin reviews1

6 studies
  1. Navitoclax induces apoptosis in BMP4-induced senescent glioblastoma cells.

    “Furthermore, navitoclax effectively eliminated BMP4-induced senescent cells through apoptosis, while sparing cells with normal p21 expression.”

    Cellsin BMP4-induced senescent glioblastoma cells

    p21-Dependent Senescence Induction by BMP4 Renders Glioblastoma Cells Vulnerable to Senolytics

    International journal of molecular sciences

  2. Navitoclax increases apoptosis in cells (combined with GPX4 or MCL-1 inhibition in some previously insensitive senescent cells).

    “significantly increased the induction of apoptosis in some, but not all, previously insensitive senescent cells”

    Cellscombined with GPX4 or MCL-1 inhibition in some previously insensitive senescent cells

    Apoptotic priming in senescence predicts specific senolysis by quantitative analysis of mitochondrial dependencies

    Cell death and differentiation

  3. Navitoclax induces apoptosis in senescent DMG cells, via Bcl-xL inhibition.

    “We identify Navitoclax as a potent senolytic agent that selectively targets senescent DMG cells into apoptosis by inhibiting Bcl-xL”

    Cellsin senescent DMG cells, via Bcl-xL inhibition

    Targeted inhibition of Bcl-xL following radiation reduces tumourigenesis in preclinical models of H3K27M-altered diffuse midline glioma

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

  4. Navitoclax induces apoptosis in senescent prostate cancer cells, from prior in vitro work.

    “the BCL-XL/BCL-2 inhibitor, ABT-263 (navitoclax), an established senolytic agent, promoted apoptosis of senescent PCa cells”

    Reviewin senescent prostate cancer cells, from prior in vitro work

    Androgen deprivation-induced senescence confers sensitivity to a senolytic strategy in prostate cancer

    Biochemical pharmacology

  5. Navitoclax induces apoptosis in DOX-induced senescent HUVECs.

    “ABT-263 (Navitoclax) selectively induced the apoptosis of DOX-induced senescent HUVECs but not EA.hy926 cells.”

    Cellsin DOX-induced senescent HUVECs

    EA.hy926 Cells and HUVECs Share Similar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263

    Cells

  6. Navitoclax induces apoptosis in cells (added after irradiation, compared with radiation alone).

    “the addition of senolytic agents Venetoclax (ABT-199) or Navitoclax (ABT-263) after irradiation induced a rapid apoptotic cell death in STS monolayer cultures”

    Cellsadded after irradiation, compared with radiation alone

    Senolytic Targeting of Bcl-2 Anti-Apoptotic Family Increases Cell Death in Irradiated Sarcoma Cells

    Cancers

More on Apoptosis

Senescent cells

downin human cells1downin humans1downin M. abscessus cells1downin rats1

4 studies
  1. Navitoclax decreases senescent cells in M. abscessus cells.

    “the senolytic drug Navitoclax selectively eradicated senescent cells”

    Cells

    Chronic infection triggers senescence in mouse immune cells

    Nature communications

  2. Navitoclax decreases senescent cells in rats (unilateral ureteral obstruction).

    “after the treatment with ABT263, the rats had a significantly lower number of senescent cells”

    Animalsunilateral ureteral obstructionkidney

    Targeted Drug Therapy for Senescent Cells Alleviates Unilateral Ureteral Obstruction-Induced Renal Injury in Rats

    Pharmaceutics

  3. Navitoclax decreases senescent cells in IR-induced senescent WI-38 cells.

    “treatment with NPs(Nav)@MMP-3 induced a selective decrease in the viability of SCs”

    Cellsin IR-induced senescent WI-38 cells

    A navitoclax-loaded nanodevice targeting matrix metalloproteinase-3 for the selective elimination of senescent cells

    Acta biomaterialia

  4. Navitoclax decreases senescent cells in humans (human skin graft mouse model).

    “Analysis of the skin specimens revealed that ABT-263 induced selective elimination of senescent dermal fibroblasts.”

    Animalshuman skin graft mouse modelskin

    Navitoclax (ABT-263) Rejuvenates Human Skin by Eliminating Senescent Dermal Fibroblasts in a Mouse/Human Chimeric Model

    Rejuvenation research

More on Senescent cells

Thrombocytopenia

upin reviews2upin cynomolgus monkeys1upin rats1

4 studies
  1. Navitoclax induces thrombocytopenia.

    “on-target toxicity (e.g., navitoclax-induced thrombocytopenia)”

    Review

    Senotherapy: scientific advances and clinical potential of senolytic therapies

    O Mundo da Saúde

  2. Navitoclax induces thrombocytopenia in young rats.

    “Moderate thrombocytopenia was induced by 10 mg/kg, and to a greater extent by 30 mg/kg.”

    Animalsin young ratsi.p.10 and 30 mg/kgmales

    The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke

    Pharmaceuticals (Basel, Switzerland)

  3. Navitoclax increases thrombocytopenia (on-target toxicity).

    “ABT-263 is unlikely to be approved for the clinical treatment of solid tumors due to both on-target (thrombocytopenia) and off-target (neutropenia) toxicities”

    Reviewon-target toxicity

    Assessing the Complexities of Utilizing BH3 Mimetics for a Senolytic Strategy in Combination with Ionizing Radiation

    Radiation research

  4. Navitoclax induces thrombocytopenia in cynomolgus monkeys (intermittent treatment in aged monkeys) (modest, reversible).

    “Intermittent treatment with the senolytic navitoclax induced modest reversible thrombocytopenia; no serious drug-related toxicity was noted.”

    Animalsintermittent treatment in aged monkeys

    Navitoclax safety, tolerability, and effect on biomarkers of senescence and neurodegeneration in aged nonhuman primates

    Heliyon

More on Thrombocytopenia

Scar size

downin animals2downin mice1

3 studies
  1. Navitoclax decreases scar size in mice after ischemia-reperfusion injury.

    “Navitoclax reduced p16INK4a-positive and p21CIP1-positive nuclei and was associated with smaller scars”

    Animalsafter ischemia-reperfusion injuryheartseven daysmales

    Navitoclax linked to smaller heart scars in middle-aged mice

    Research SquarePreprint

  2. Navitoclax decreases scar size after ischemia-reperfusion.

    “improves left ventricular function, increases myocardial vascularization, and decreases scar size”

    Animalsafter ischemia-reperfusionheart

    Clearance of senescent cells during cardiac ischemia-reperfusion injury improves recovery

    Aging cell

  3. Navitoclax decreases scar size after cardiac ischemia-reperfusion injury.

    “treatment with the senolytic drug navitoclax after ischemia-reperfusion improves left ventricular function, increases myocardial vascularization, and decreases scar size”

    Animalsafter cardiac ischemia-reperfusion injuryheart

    Clearance of senescent cells following cardiac ischemia-reperfusion injury improves recovery

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

Cell viability

downin human cells2downin rat cells1

3 studies
  1. Navitoclax decreases cell viability in rat cells (senescent cardiac myofibroblasts induced by TGF-β1).

    “Treatment with Navitoclax or Dasatinib + Quercetin decreased cell viability and reduced the proportion of SA-β-gal -positive cells.”

    Cellssenescent cardiac myofibroblasts induced by TGF-β1

    Simultaneous induction of differentiation and senescence in cardiac fibroblasts by TGF-β1: effects of senotherapeutics drugs

    Frontiers in pharmacology

  2. Navitoclax decreases cell viability in OE cyst-derived stromal cells (CSCs) (P < 0.01).

    “AZM and ABT263 reduced the viable fraction in CSCs (AZM: P < 0.001, ABT263: P < 0.01).”

    Cellsin OE cyst-derived stromal cells (CSCs)

    A novel senotherapeutic strategy with azithromycin for preventing endometriosis progression

    Reproductive biology and endocrinology : RB&E

  3. Navitoclax decreases cell viability in cells cultured at 37°C.

    “Navitoclax was most effective in eliminating senescent cells.”

    Cellsin cells cultured at 37°C

    A Human Conditionally Immortalized Proximal Tubule Epithelial Cell Line as a Novel Model for Studying Senescence and Response to Senolytics

    Frontiers in pharmacology

Mortality

upin mice2upin reviews1

3 studies
  1. Navitoclax increases mortality (advanced atherosclerosis model).

    “increasing EndoMT and mortality risk”

    Reviewadvanced atherosclerosis model

    Rapid Evidence Synthesis: Senolytics May Backfire in Advanced Plaques

    Preprint

  2. Navitoclax increases mortality in western diet-fed Apoe-/- mice with advanced atherosclerosis (> 50%).

    “ABT-263 treatment also reduced α-SMA+ fibrous cap thickness by 60% and was associated with a > 50% mortality rate.”

    Animalsin western diet-fed Apoe-/- mice with advanced atherosclerosis100 mg/kg/bw or 50 mg/kg/bw6 weeks or 9 weeks

    Treatment of advanced atherosclerotic mice with ABT-263 reduced indices of plaque stability and increased mortality

    JCI insight

  3. Navitoclax increases mortality in WD-fed Apoe-/- mice (>50%).

    “and increased mortality by >50%.”

    Animalsin WD-fed Apoe-/- mice

    Treatment of advanced atherosclerotic mice with the senolytic agent ABT-263 is associated with reduced indices of plaque stability and increased mortality

    bioRxiv : the preprint server for biologyPreprint

Spatial memory

upin mice3

3 studies
  1. Navitoclax improves spatial memory in APP/PS1 mice, Morris water maze.

    “ABT263 alleviated spatial memory impairment”

    Animalsin APP/PS1 mice, Morris water mazetwo cycles of five days eachn = 16

    ABT263 Ameliorates Cellular Senescence, Aβ-Dependent Pathology and Cognitive Decline in Aged APP/PS1 Mice via Regulating PI3K/AKT/GSK-3β Pathways

    Cell biochemistry and biophysics

  2. Navitoclax improves spatial memory in mice (atherosclerotic LDLr-/-; hApoB100+/+ mice, prevention treatment).

    “In young male ATX mice, prevention with ABT-263 improved spatial retention memory”

    Animalsatherosclerotic LDLr-/-; hApoB100+/+ mice, prevention treatment3 monthsmales

    The senolytic ABT-263 improves cognitive functions in middle-aged male, but not female, atherosclerotic LDLr-/-;hApoB₁₀₀+/+ mice

    GeroScience

  3. Navitoclax improves spatial memory in mice (one month after treatment).

    “One month post-ABT-263, adult-born hippocampal neuron numbers increased and hippocampus-dependent spatial memory was enhanced.”

    Animalsone month after treatmentone month post-treatment

    Restoration of hippocampal neural precursor function by ablation of senescent cells in the aging stem cell niche

    Stem cell reports

Partial response

upin humans1

1 study
  1. Navitoclax induces partial response in humans (relapsed or refractory lymphoid malignancies) (10 of 46 patients with assessable disease).

    “Ten of 46 patients with assessable disease had a partial response”

    Human trialrelapsed or refractory lymphoid malignanciesn = 46

    Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

    The Lancet. Oncology

  2. Navitoclax induces partial response in humans.

    “Furthermore, 10 of these patients achieved a partial response (PR) lasting a median (range) of 455 days (IQR 40–218).”

    Human trialn = 46

    Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

    The Lancet. Oncology

T cell lymphopenia

upin humans1OR 4

1 study
  1. Navitoclax induces T cell lymphopenia in humans (attributed to high-affinity BCL-2 inhibition) (grade 3 or 4 lymphocytopenia in 18 patients).

    “Navitoclax has a novel mechanism of peripheral thrombocytopenia and T-cell lymphopenia, attributable to high-affinity inhibition of BCL-XL and BCL-2, respectively.”

    Human trialattributed to high-affinity BCL-2 inhibition

    Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

    The Lancet. Oncology

More on T cell lymphopenia

Peripheral thrombocytopenia

upin humans1OR 4

1 study
  1. Navitoclax induces peripheral thrombocytopenia in humans (attributed to high-affinity BCL-XL inhibition) (grade 3 or 4 thrombocytopenia in 29 patients).

    “Navitoclax has a novel mechanism of peripheral thrombocytopenia and T-cell lymphopenia, attributable to high-affinity inhibition of BCL-XL and BCL-2, respectively.”

    Human trialattributed to high-affinity BCL-XL inhibition

    Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

    The Lancet. Oncology

More on Peripheral thrombocytopenia

Platelet count

downin humans1

1 study
  1. Navitoclax decreases platelet count in humans.

    “There was a significant reduction following a single dose of navitoclax, which was observed to begin as soon as one hour after dosing (data not shown).”

    Human trialn = 55

    Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

    The Lancet. Oncology

More on Platelet count

All 198

What is navitoclax linked with?

4

Studies link navitoclax with 4 measures, among them ETS1, cerebral microhemorrhage and hematological toxicity.

ETS1

upin silico1

1 study
  1. Navitoclax is associated with ETS1 in silico (molecular docking prediction).

    “Molecular docking revealed favorable binding affinity between senolytic Navitoclax and these potential biomarkers.”

    In silicomolecular docking prediction

    Identification of senescence-related genes for potential therapeutic biomarkers of atrial fibrillation by bioinformatics, human histological validation, and molecular docking

    Heliyon

More on ETS1

Cerebral microhemorrhage

downin mice1

1 study
  1. Navitoclax lowers the risk of cerebral microhemorrhage in mice (hypertension induced by angiotensin-II and L-NAME).

    “Notably, the senolytic pre-treatment wielded considerable cerebromicrovascular protection, effectively delaying the onset, mitigating the incidence, and diminishing the severity of CMHs.”

    Animalshypertension induced by angiotensin-II and L-NAMEbrain

    Preventing spontaneous cerebral microhemorrhages in aging mice: a novel approach targeting cellular senescence with ABT263/navitoclax

    GeroScience

More on Cerebral microhemorrhage

Hematological toxicity

upin reviews1

1 study
  1. Navitoclax is associated with hematological toxicity.

    “navitoclax, which is associated with hematological toxicity”

    Review

    New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463

    Aging

More on Hematological toxicity

Thrombocytopenia

upin humans1

1 study
  1. Navitoclax raises the risk of thrombocytopenia in humans (29 patients).

    “Thrombocytopenia and neutropenia were the serious common toxicities with grade 3 or 4 thrombocytopenia or neutropenia observed in 29 and 17 patients, respectively.”

    Human trialn = 55

    Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

    The Lancet. Oncology

More on Thrombocytopenia

Has navitoclax been tested in people?

0 of 28 about aging

Yes: 2 trials and 16 observational studies in people have been published, and 28 trials are registered.

In trials

  • Tumor

    Phase 3Results posted8 trials

  • Primary myelofibrosis

    Phase 3Results posted7 trials

  • Leukemia, Lymphocytic, Chronic, B-Cell

    Phase 2Completed2 trials

  • Splenomegaly

    Phase 2Results posted1 trial

  • Neoplasm metastasis

    Phase 1/2Active, not recruiting3 trials

  • Precursor cell lymphoblastic leukemia lymphoma

    Phase 1/2Active, not recruiting3 trials

All 26

Stopped

  • NCT03366103TerminatedNeoplasm metastasis

    Drug supply issues

Who is developing navitoclax?

1 company: AbbVie.

Companies
  • AbbViePhase 3myelofibrosis, cd20 positive lymphoid malignancy

Trial sponsors

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Navitoclax decreases cellular senescence in mice across independent labs; independent labs also report increased inflammation in mice and decreased inflammation in rats. One group reports thrombocytopenia in a human trial whose paper declares developer ties; most trials are developer-sponsored. None of its registered trials concern aging, and 10 ended over a year ago without posted results.

  2. Summary rewritten as its findings changed.

    As it read before

    Navitoclax extends lifespan with cyclic dosing in Titan mice; independent labs reproduce reduced senescence and SASP in mice. In mice with advanced atherosclerosis, it increases mortality without shrinking lesions. None of its registered trials is judged aging-related; ten ended over a year ago without posted results or citing papers, and most trials are sponsored by AbbVie and Genentech.

  3. Summary rewritten as its findings changed.

    As it read before

    Navitoclax reduces cardiac senescence, hypertrophy and scarring and increases angiogenesis after ischemia–reperfusion injury in male mice in a preprint. A cell study reports reduced senescent cells and M. abscessus burden; a zebrafish study reports fewer senescent hepatocytes with high UHRF1.

  4. Summary written from the findings.

Latest

Dec 2025: 8Jan 2026: 10Feb 2026: 5Mar 2026: 8Apr 2026: 8May 2026: 4Jun 2026: 4Jul 2026: 5Aug 2026: 3Sep 2026: 2Oct 2026: 5Nov 2026: 466 papers in 12 months
bioRxiv

Protein levels alter drug sensitivity in lab-grown human cells

Cells still stopped dividing after radiation, but protein levels changed their secreted signals and sensitivity to a drug that kills senescent cells.Cells still stopped dividing after radiation, but protein levels changed their secreted signals and sensitivity to a drug that kills senescent cells.

Preprint: human cell studyMechanisms
Journal of Controlled Release

Drug-filled particles reduced liver fat buildup in mice

An experiment tested navitoclax in mice with diet-induced liver disease; the packaged drug also reduced a disease activity score and scarring-related profiles.An experiment tested navitoclax in mice with diet-induced liver disease; the packaged drug also reduced a disease activity score and scarring-related profiles.

Mouse studyInterventions
Neuro-oncology

Drug combination limited brain tumor regrowth in mice

In mice carrying childhood brain tumor models, trametinib plus navitoclax reduced regrowth after treatment stopped and improved survival.In mice carrying childhood brain tumor models, trametinib plus navitoclax reduced regrowth after treatment stopped and improved survival.

Mouse studyInterventions
International Journal of Radiation Oncology, Biology, Physics

Drug reduced radiation-induced skin scarring in mice

In an experiment with at least 10 mice per group, ABT-263 also depleted connective-tissue and immune cells linked to scarring.In an experiment with at least 10 mice per group, ABT-263 also depleted connective-tissue and immune cells linked to scarring.

Mouse studySkin
Cell Death & Disease

Lowering a protein reduced drug sensitivity in senescent cells

In laboratory experiments, reducing the protein weakened two drugs’ cell-killing effects without changing the usual signs of senescence, a state in which cells stop…In laboratory experiments, reducing the protein weakened two drugs’ cell-killing effects without changing the usual signs of senescence, a state in which cells stop dividing.

See all 299 papers on navitoclax